Calcitonin and procalcitonin in patients with medullary thyroid cancer or bacterial infection

Advances in Clinical and Experimental Medicine

Volumn 21, Issue 2, 2012, Pages 169-178

  Kaczka, Krzysztof ^a   Mikosiński, Sławomir ^b   Fendler, Wojciech ^a   Celnik, Agnieszka ^a   Pomorski, Lech ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Department of Nuclear Medicine and Oncological Endocrinology   (Poland)

Author keywords

Calcitonin; Medullary thyroid cancer; Procalcitonin

Indexed keywords

BIOLOGICAL MARKER; CALCITONIN; PROCALCITONIN;

ADULT; ARTICLE; BACTERIAL INFECTION; CALCITONIN BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NODULAR GOITER; OUTCOME ASSESSMENT; REMISSION; SEPSIS; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

EID: 84862559262     PISSN: 18995276     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. 3 1α-Hydroxylase Gene. J Biol Chem 2009, 284, 11059-11069.
2. Constante G, Merongolo D, Durante C, Bianchi D, Nocera M, Tumino S et al.: Predictive value of serum calcitonin levels for preoperative diagnosis of medullary in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007, 92, 450-455.
3. Pomorski L, Cywiński J, Kołomecki K, Pasieka Z, Bartos M, Kuzdak K: Recurrences of thyroid cancer after radical surgery and complementary treatment: are macroscopic, microscopic, scintigraphic, and biochemical criteria sufficient in the evaluation of radicality of primary treatment? Recent Results Cancer Res 2003, 162, 203-207.
4. Niccoli P, Wion-Barbot N, Caron P, Henry JF, de Micco C, Saint Andre JP et al.: Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab 1997, 82, 338-341.
5. Lew-Bohbot N, Patey M, Larbre M, Hecart AC, Caron J, Delemer B: How to interprete hypercalcitonemia. Rev Med Intern 2006, 27, 610-615.
6. Iacobone M, Niccoli-Sire P, Sebag F De Micco C, Henry JF: Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels. World J Surg 2002, 26, 886-890.
7. Algecitras-Schimnich A, Preissner C, Theobald P, Finseth MS, Grebe SK: Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrin Metab 2008, 94, 861-868.
8. Akan B, Böhmig G, Sunder-Plassmann G, Borchhardt KA: Prevalence of hypercalcitoninemia in patients on maintenance dialysis referred to kidney transplantation. Clin Nephrol 2009, 71, 538-542.
9. Tomamsi M, Brocchi A, Cappellini A, Raspanti S, Mannelli M: False serum calcitonin high levels using a non-competitive two-site IRMA. J Endocrinol Invest 2001, 24, 356-360.
10. Cole TG, Johnson D, Eveland BJ, Nahm MH: Cost-effective method for detection of "hook effect" in tumor marker immunometric assays. Clin Chem 1993, 39, 695-696.
11. Leboeuf R, Langlois MF, Martin M, Ahnadi CE, Fink GD: "Hook Effect" in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature. J Clin Endocrin Metab 2006, 91, 361-364.
12. Leboulleux S, Baudin E, Travagli JP, Schlumberger M: Medullary thyroid carcinoma 2004, 61, 299-310.
13. Morimoto S, Onishi T, Takamoto S, Imanaka S, Fukuo K, Tsuchiya H et al.: Interference in radioimmunoassay of human calcitonin by vitamin C and urea. Med J Osaka Univ 1985, 35, 77-82.
14. Summah H, Qu JM: Biomarkers: a definite plus in pneumonia. Mediators Inflamm 2009, 2009, 675-753.
15. Bihan H, Becker KL, Snider RH, Nylen E, Vittaz L, Lauret C et al.: Calcitonin precursor levels in human medullary thyroid carcinoma. Thyroid 2003, 13, 819-822.
16. Chastre J, Luyt CE, Trouillet JL, Combes A: New diagnostic and prognostic markers of ventilator-associated pneumonia. Curr Opin Crit Care 2006, 12, 446-451
17. Meisner M, Schmidt J, Hüttner H, Tschaikowski K: The natural elimination rate of procalcitonin in patients with normal and impaired renal function. Intensive Care Med 2000, 26 Suppl 2, S21 12-16.
18. Shehabi Y, Seppelt I: Pro/Con debate: is procalcitonin useful for guiding antibiotic decision making in critically ill patients? Crit Care 2008, 12, 211.
19. Vierhapper H, Niederle B, Bieglmayer C, Kaserer K, Baumgartner-Parzer S: Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. Thyroid 2005, 15, 1267-1272.
20. Vantyghem MC, Pigny P, Leteurtre E, Leclerc L, Bauters C, Douillard C et al.: Thyroid carcinomas involving follicular and parafollicular C cells: seventeen cases with characterization of RET oncogenic activation. Thyroid 2004, 14, 842-847.
21. Hasselgren M, Hegedüs L, Godballe C, Bonnema SJ: Benefit of measuring basal serum calcitonin to detect medullary thyroid carcinoma in a Danish population with a high prevalence of thyroid nodules. Head Neck 2010, 32, 612-618.
22. Papi G, Corsello SM, Cioni K, Pizzini AM, Corrado S, Carapezzi C et al.: Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: A multicenter study. J Endocrinol Invest 2006, 29, 427-437.
23. Borget I, De Pouvourville G, Schlumberger M: Editorial: calcitonin determination in patients with nodular thyroid disease. J Clin Endocrinol Metab 2007, 92, 425-427.
24. Martinetti A, Seregni E, Ferrari L, Pallotti F, Aliberti G, Coliva A et al.: Evaluation of circulating calcitonin analytical aspects. Tumori 2003, 89, 566-568.
25. Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR et al.: Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006, 174, 84-93.
26. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J: Use of procalcitonin to shorten antibiotic treatment duration in septic patients. A randomized trial. Am J Respir Crit Care Med 2008, 177, 498-505.
27. Matzaraki V, Alexandraki KI, Venetsanou K et al.: Evaluation of serum procalcitonin and interleukin-6 levels markers of liver metastasis. Clin Biochem 2007, 40, 336-342.
28. Algeciras-Schimnich A, Preissner CM, Theobald JP, Finseth MS, Grebe SK: Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2009, 94, 861-868.